Effect of Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Tiotropium: The HELIOS Study (BY217/M2-128)

This study has been completed.
Sponsor:
Information provided by:
Takeda
ClinicalTrials.gov Identifier:
NCT00424268
First received: January 18, 2007
Last updated: May 4, 2012
Last verified: August 2011
  Purpose

The aim of the study is to compare the efficacy of roflumilast to placebo on pulmonary function and symptomatic parameters in patients with chronic obstructive pulmonary disease (COPD) during concomitant administration of tiotropium. The study duration will last up to 28 weeks. The study will provide further data on safety and tolerability of roflumilast.


Condition Intervention Phase
Chronic Obstructive Pulmonary Disease
Drug: Roflumilast
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Effect of Roflumilast in COPD Patients Treated With Tiotropium. A 24-week, Double-blind Study With 500 µg Roflumilast Once Daily Versus Placebo. The HELIOS Study

Resource links provided by NLM:


Further study details as provided by Takeda:

Primary Outcome Measures:
  • Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1) [ Time Frame: Change from baseline over 24 weeks of treatment ] [ Designated as safety issue: No ]
    Mean change from baseline during the treatment period in pre-bronchodilator FEV1 [L]


Secondary Outcome Measures:
  • Post-bronchodilator FEV1 [ Time Frame: Change from baseline over 24 weeks of treatment ] [ Designated as safety issue: No ]
    Mean change from baseline during the treatment period in post-bronchodilator FEV1 [L]

  • COPD Exacerbation Rate (Moderate or Severe) [ Time Frame: 24 weeks treatment period ] [ Designated as safety issue: No ]

    Mean rate of COPD exacerbations requiring oral or parenteral glucocorticosteroids (=moderate COPD exacerbations), or requiring hospitalization, or leading to death (=severe COPD exacerbations), per patient per year.

    A COPD exacerbation is an event in the natural course of the disease characterized by a change in the patient's baseline dyspnea, cough and/or sputum beyond day-to-day variability sufficient to warrant a change in management [American Thoracic Society (ATS) / European Respiratory Society (ERS) 2005].


  • Transition Dyspnea Index (TDI) Focal Score [ Time Frame: Change from baseline over 24 weeks of treatment ] [ Designated as safety issue: No ]

    The TDI is a recognized questionnaire to measure dyspnea in an out patient COPD population. At baseline, 3 components of dyspnea, each graded with 4 questions, were asked:

    • Functional Impairment
    • Magnitude of Task
    • Magnitude of Effort

    At each of the post-randomization visits questions from the TDI were asked related to 3 components:

    Change in

    • Functional Impairment
    • Magnitude of Task
    • Magnitude of Effort

    Each question in the TDI is graded from -3 (major deterioration) to +3 (major improvement). This results in a TDI Focal Score ranging from -9 to +9.


  • Shortness of Breath Questionnaire (SOBQ) Total Score [ Time Frame: Change from baseline over 24 weeks of treatment ] [ Designated as safety issue: No ]

    Mean change from baseline during the treatment period in SOBQ. This is a 24-item measure that assesses self-reported shortness of breath while performing a variety of activities of daily living.

    The questions were administered at visits V0, V2, V3, V4, V5, V6 and Vend to assess the perceived shortness of breath of the patient.

    For each activity listed in the questionnaire the patient should rate his/her breathlessness on a scale between zero and five, where zero is "not at all breathless" and five is "maximally breathless or too breathless to do the activity".



Enrollment: 743
Study Start Date: January 2007
Study Completion Date: July 2008
Primary Completion Date: January 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Roflumilast

Roflumilast 500 µg

underlying medication: tiotropium 18 µg, once daily, inhaled

Drug: Roflumilast
500 µg, once daily, oral administration in the morning
Placebo Comparator: Placebo

Placebo

underlying medication: tiotropium 18 µg, once daily, inhaled

Drug: Placebo
once daily

  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Main Inclusion Criteria:

  • History of COPD for at least 12 months prior to baseline visit and chronic productive cough for 3 months in each of the 2 years prior to baseline visit
  • FEV1/FVC ratio (post-bronchodilator) ≤ 70%
  • FEV1 (post-bronchodilator) between ≥ 40% and ≤ 70% of predicted
  • Treated with tiotropium for at least 3 months before enrollment
  • At least 28 puffs of rescue medication during last week prior to randomization

Main Exclusion Criteria:

  • COPD exacerbation indicated by a treatment with systemic glucocorticosteroids and/or antibiotics not stopped at least 4 weeks prior to baseline visit
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00424268

  Hide Study Locations
Locations
Austria
Altana Pharma/Nycomed Investigational Site
Feldbach, Austria, 8330
Altana Pharma/Nycomed Investigational Site
Gänserndorf, Austria, 2230
Altana Pharma/Nycomed Investigational Site
Hallein, Austria, 5400
Altana Pharma/Nycomed Investigational Site
Linz, Austria, 4040
Altana Pharma/Nycomed Investigational Site
Spittal an der Drau, Austria, 9800
France
Altana Pharma/Nycomed Investigational Site
Beuvry, France, 62660
Altana Pharma/Nycomed Investigational Site
Chauny Cedex, France, 2303
Altana Pharma/Nycomed Investigational Site
Grasse, France, 6130
Altana Pharma/Nycomed Investigational Site
Lyon, France, 69003
Altana Pharma/Nycomed Investigational Site
Martigues Cedex, France, 13695
Altana Pharma/Nycomed Investigational Site
Montigny-Les-Metz, France, 57950
Altana Pharma/Nycomed Investigational Site
Nantes, France, 44000
Altana Pharma/Nycomed Investigational Site
Nice, France, 6000
Altana Pharma/Nycomed Investigational Site
Nimes, France, 30900
Altana Pharma/Nycomed Investigational Site
Nimes Cedex 9, France, 30029
Altana Pharma/Nycomed Investigational Site
Ollioules, France, 83190
Altana Pharma/Nycomed Investigational Site
Perpignan Cedex, France, 66046
Altana Pharma/Nycomed Investigational Site
Saint Laurent Du Var, France, 6700
Altana Pharma/Nycomed Investigational Site
Saint-Quentin, France, 2100
Altana Pharma/Nycomed Investigational Site
Toulon, France, 83000
Germany
Altana Pharma/Nycomed Investigational Site
Bad Homburg, Germany, 61348
Altana Pharma/Nycomed Investigational Site
Dortmund, Germany, 44263
Altana Pharma/Nycomed Investigational Site
Geesthacht, Germany, 21502
Altana Pharma/Nycomed Investigational Site
Gelnhausen, Germany, 63571
Altana Pharma/Nycomed Investigational Site
Göppingen, Germany, 73033
Altana Pharma/Nycomed Investigational Site
Hannover, Germany, 30167
Altana Pharma/Nycomed Investigational Site
Koblenz, Germany, 56068
Altana Pharma/Nycomed Investigational Site
Landsberg/Lech, Germany, 86899
Altana Pharma/Nycomed Investigational Site
Leonberg, Germany, 71229
Altana Pharma/Nycomed Investigational Site
Marburg, Germany, 35037
Altana Pharma/Nycomed Investigational Site
Saarbrücken, Germany, 66111
Altana Pharma/Nycomed Investigational Site
Saarlouis, Germany, 66740
Altana Pharma/Nycomed Investigational Site
Schwetzingen, Germany, 68723
Altana Pharma/Nycomed Investigational Site
Sinsheim, Germany, 74889
Altana Pharma/Nycomed Investigational Site
Weyhe, Germany, 28844
Altana Pharma/Nycomed Investigational Site
Witten, Germany, 58452
Hungary
Altana Pharma/Nycomed Investigational Site
Budapest, Hungary, 1134
Altana Pharma/Nycomed Investigational Site
Budapest, Hungary, 1046
Altana Pharma/Nycomed Investigational Site
Budapest, Hungary, 1529
Altana Pharma/Nycomed Investigational Site
Cegled, Hungary, 2700
Altana Pharma/Nycomed Investigational Site
Csorna, Hungary, 9300
Altana Pharma/Nycomed Investigational Site
Erd, Hungary, 2030
Altana Pharma/Nycomed Investigational Site
Györ, Hungary, 9024
Altana Pharma/Nycomed Investigational Site
Hódmezovásárhely, Hungary, 6800
Altana Pharma/Nycomed Investigational Site
Matrahaza, Hungary, 3233
Altana Pharma/Nycomed Investigational Site
Nyiregyháza, Hungary, 4412
Altana Pharma/Nycomed Investigational Site
Szentes, Hungary, 6600
Altana Pharma/Nycomed Investigational Site
Szolnok, Hungary, 5006
Italy
Altana Pharma/Nycomed Investigational Site
Bassano Del Grappa (VI), Italy, 36061
Altana Pharma/Nycomed Investigational Site
Cisanello (PI), Italy, 56100
Altana Pharma/Nycomed Investigational Site
Foggia, Italy, 71100
Altana Pharma/Nycomed Investigational Site
Genova, Italy, 16132
Altana Pharma/Nycomed Investigational Site
Milano, Italy, 20153
Altana Pharma/Nycomed Investigational Site
Modena, Italy, 41100
Altana Pharma/Nycomed Investigational Site
Pavullo nel Frignano (MO), Italy, 41020
Altana Pharma/Nycomed Investigational Site
Pordenone, Italy, 33170
Altana Pharma/Nycomed Investigational Site
Reggio Emilia, Italy, 42100
Altana Pharma/Nycomed Investigational Site
Verona, Italy, 30012
Spain
Altana Pharma/Nycomed Investigational Site
Alicante, Spain, 3010
Altana Pharma/Nycomed Investigational Site
Baracaldo (Vizcaya), Spain, 48903
Altana Pharma/Nycomed Investigational Site
Candia, Spain, 28935
Altana Pharma/Nycomed Investigational Site
Escaldes-Engordany, Spain, AD700
Altana Pharma/Nycomed Investigational Site
Galdakao, Spain, 48960
Altana Pharma/Nycomed Investigational Site
Guadalajara, Spain, 19002
Altana Pharma/Nycomed Investigational Site
Jerez de la Frontera, Spain, 11407
Altana Pharma/Nycomed Investigational Site
La Coruna, Spain, 15006
Altana Pharma/Nycomed Investigational Site
Lleida, Spain, 25198
Altana Pharma/Nycomed Investigational Site
Lugo, Spain, 27004
Altana Pharma/Nycomed Investigational Site
Madrid, Spain, 28047
Altana Pharma/Nycomed Investigational Site
Madrid, Spain, 28007
Altana Pharma/Nycomed Investigational Site
Madrid, Spain, 28034
Altana Pharma/Nycomed Investigational Site
Mostoles Madrid, Spain, 28935
Altana Pharma/Nycomed Investigational Site
Pozuelo de Alarcón, Spain, 28223
Altana Pharma/Nycomed Investigational Site
Requena, Spain, 46340
Altana Pharma/Nycomed Investigational Site
Sant Cugat del Valles, Spain, 8190
Altana Pharma/Nycomed Investigational Site
Santa Cruz de Tenerife, Spain, 38010
Altana Pharma/Nycomed Investigational Site
Sevilla, Spain, 41013
Altana Pharma/Nycomed Investigational Site
Valencia, Spain, 46017
Altana Pharma/Nycomed Investigational Site
Valencia, Spain, 46014
Altana Pharma/Nycomed Investigational Site
Valencia, Spain, 46010
Altana Pharma/Nycomed Investigational Site
Valencia, Spain, 46015
United Kingdom
Altana Pharma/Nycomed Investigational Site
Ashford, United Kingdom, TW15 3RN
Altana Pharma/Nycomed Investigational Site
Atherstone, Warwick, United Kingdom, CV9 1EU
Altana Pharma/Nycomed Investigational Site
Barry, United Kingdom, CS62 7EB
Altana Pharma/Nycomed Investigational Site
Bexhill-on-Sea, East Sussex, United Kingdom, TN40 1JJ
Altana Pharma/Nycomed Investigational Site
Bolton, United Kingdom
Altana Pharma/Nycomed Investigational Site
Bolton Lancs, United Kingdom, BL3 6TL
Altana Pharma/Nycomed Investigational Site
Chesterfield, United Kingdom, S40 4TF
Altana Pharma/Nycomed Investigational Site
Chesterfield Derbyshire, United Kingdom, S40 4TF
Altana Pharma/Nycomed Investigational Site
Chippenham, United Kingdom, SN15 1HP
Altana Pharma/Nycomed Investigational Site
Co. Antrim, United Kingdom, BT38 8TP
Altana Pharma/Nycomed Investigational Site
Darlington, Co. Durham, United Kingdom, DL3 6HX
Altana Pharma/Nycomed Investigational Site
East Sussex, United Kingdom, TN39 5HE
Altana Pharma/Nycomed Investigational Site
Glasgow, United Kingdom, G45 9AW
Altana Pharma/Nycomed Investigational Site
Harrow, United Kingdom, HA3 7LT
Altana Pharma/Nycomed Investigational Site
Keresely End, Coventry, United Kingdom, CV7 8LA
Altana Pharma/Nycomed Investigational Site
Plymouth, United Kingdom, PL6 7TH
Altana Pharma/Nycomed Investigational Site
Sheffield, United Kingdom, S39DA
Altana Pharma/Nycomed Investigational Site
Solihull, United Kingdom, B91 2JL
Altana Pharma/Nycomed Investigational Site
Swindon, Wilts, United Kingdom, SN25 4YZ
Altana Pharma/Nycomed Investigational Site
Trowbridge, United Kingdom, BA14 9AR
Altana Pharma/Nycomed Investigational Site
Watford, United Kingdom, WD25 0EA
Altana Pharma/Nycomed Investigational Site
Yaxley, United Kingdom, PE7 3JL
Sponsors and Collaborators
Takeda
Investigators
Principal Investigator: Prof. L M Fabbri University of Modena & Reggio Emilia, Department of Respiratory Diseases, Italy
  More Information

No publications provided by Takeda

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Nycomed
ClinicalTrials.gov Identifier: NCT00424268     History of Changes
Other Study ID Numbers: BY217/M2-128, 2006-004508-37
Study First Received: January 18, 2007
Results First Received: March 17, 2011
Last Updated: May 4, 2012
Health Authority: Austria: Federal Office for Safety in Health Care
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: Federal Institute for Drugs and Medical Devices
Hungary: National Institute of Pharmacy
Italy: The Italian Medicines Agency
Spain: Spanish Agency of Medicines
United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by Takeda:
COPD
Roflumilast

Additional relevant MeSH terms:
Lung Diseases
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Respiratory Tract Diseases
Tiotropium
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Asthmatic Agents
Respiratory System Agents
Therapeutic Uses
Parasympatholytics
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 28, 2014